News Releases

Year 2010 Year 2009 Year 2008 Year 2007

Response Biomedical Corporation Announces Second Quarter Results
Tue, 10 Aug 2010 11:30:00 UT
Response Biomedical Corporation today announced financial results for the second quarter and six months ended June 30, 2010. Revenue from product sales for the three month period ended June 30, 2010 increased 2% to $2,112,424 from $2,067,194 for the same period in 2009. Clinical products revenue for the three month period ended June 30, 2010 increased 10% to $1,985,675 from $1,805,308 for the same period in 2009. Contract ser ...
More...

---

Response Biomedical Corporation Closes $8 Million Private Placement
Wed, 28 Jul 2010 21:14:00 UT
Response Biomedical Corporation (the “Company”) announced today that it has closed its previously announced private placement of common shares for gross proceeds of approximately $8 million. The Company issued 13,333,333 common shares at a price of C$0.60 per share. The purchasers are affiliates of OrbiMed Advisors, LLC. The shares issued under the private placement will have a hold period under Canadian law of four months an ...
More...

---

Response Biomedical Corporation Shareholders Approve $8 Million Private Placement
Tue, 27 Jul 2010 16:24:00 UT
Response Biomedical Corporation (the “Company”) announced that at the Company’s Special General Shareholders’ Meeting held today in Vancouver, shareholders approved the private placement of an aggregate of 13,333,333 common shares (the “Offered Shares”), at a price of Cdn. $0.60 per Offered Share, to Caduceus Private Investments III, LP, OrbiMed Associates III, LP and Caduceus Asia Partners, LP (the “Purchasers”) for gross pr ...
More...

---

Response Biomedical Corporation Announces Subscription Agreement for $8 Million Private Placement
Mon, 28 Jun 2010 12:00:00 UT
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBF) announced today the signing of a subscription agreement providing for the sale of C$8 million of its common shares to funds affiliated with OrbiMed Advisors, LLC. The closing of the private placement is subject to receipt of all necessary regulatory approvals, including the approval of the Toronto Stock Exchange (“TSX”) and the shareholders of the Company. A shareholders’ meeting to approve the ...
More...

---

Response Biomedical Corporation to Present at Noble Financial Sixth Annual Equity Conference – ONTRACK 2010
Thu, 3 Jun 2010 09:00:00 UT
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBFD) today announced that S. Wayne Kay, Chief Executive Officer, will make a presentation regarding the business strategy of the Company at the Noble Financial Sixth Annual Equity Conference at 12:00 p.m. EDT on Tuesday, June 8, 2010, in Hollywood, Florida. The presentation will be Web cast – audio/video/PowerPoint – live, and available for viewing at www.responsebio.com on the “Newsroom”, “Events C ...
More...

---

Response Biomedical Corporation Announces Share Consolidation
Wed, 26 May 2010 21:08:00 UT
Response Biomedical Corporation today announced that the Company has effected a share consolidation in accordance with the authority granted by shareholders at the Company’s annual general and special meeting on May 4, 2010 to permit it to implement a consolidation of the Company’s outstanding common shares on a ten (old) for one (new) basis. The common shares are expected to begin trading on the Toronto Stock Exchange and the OTC Bulletin Boa ...
More...

---

Response Biomedical Corporation Granted Class 3 Medical Device License by Health Canada to Market RSV Assay in Canada
Mon, 17 May 2010 12:00:00 UT
VANCOUVER, British Columbia--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM; OTCBB: RPBIF) today announced that it has been granted a Class 3 (near patient/point-of-care) Medical Device license by Health Canada to market its RAMP® Respiratory Syncytial Virus (RSV) Assay in Canada. The test, manufactured by Response Biomedical, runs on the RAMP® 200 Reader and is a qualitative immunochromatographic assay indicated for use as an in vitro diagnostic product to detect the presence of RSV ...
More...

---

Response Biomedical Corporation Announces First Quarter Results
Tue, 4 May 2010 12:00:00 UT
Response Biomedical Corporation today announced financial results for the first quarter ended March 31, 2010. Total revenues for the three month period ended March 31, 2010 decreased 43% to $1,549,479 compared to $2,712,401 for the same period last year. Expenses for the three month period ended March 31, 2010 increased 18% to $2,747,614 compared to $2,326,336 for the same period last year. Net loss increased by 54% to $2,660 ...
More...

---

Response Biomedical Corporation to Present at Roth 22nd Annual OC Growth Stock Conference
Tue, 16 Mar 2010 12:00:00 UT
Response Biomedical Corporation reported that S. Wayne Kay, Chief Executive Officer, will present at the Roth 22nd Annual OC Growth Stock Conference on March 16, 2010. The Roth conference is being held at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Kay is scheduled to present on Tuesday, March 16th at 9:00 a.m. Pacific Time. The audio broadcast of this presentation can be accessed at http://www.wsw.com/webcast/roth ...
More...

---

Response Biomedical Corporation Announces 2009 Financial Results
Thu, 11 Mar 2010 12:00:00 UT
Response Biomedical Corporation reported that it recorded total revenues of $9,946,269, an increase of 69% compared to $5,876,337 in 2008. Clinical products revenue for the year ended December 31, 2009 increased 85% to $6,828,651 compared to $3,683,706 in 2008. For the year ended December 31, 2009, the Company reported a net loss of $9,543,531 or $0.04 per share compared to a loss of $13,663,656 or $0.10 per share in 2008. Additionally, the Co ...
More...

---

Response Biomedical Announces Additional Chinese Partnership
Mon, 1 Feb 2010 13:00:00 UT
Response Biomedical Corporation announced that the Company has signed a second partner, Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) in China to sell the Company’s diagnostic products, expanding its strategic presence in this important global market. “We have already seen great success in China with our first partner, O&D Biotech Co., Ltd. China (O&D), selling our co-branded RAMP® cardiac products over ...
More...

---

Response Biomedical Pre-Announces 2009 Year-End Revenues
Mon, 11 Jan 2010 13:00:00 UT
Response Biomedical Corporation announced that the Company expects to report annual revenues of approximately $10 million in 2009, as compared to $5.876 million in 2008. The Company will host a conference call and announce complete fourth quarter and year-end financial results on March 25th. “This is an exciting time in the Company’s history, with 2009 being a record year for overall revenue. These results are con ...
More...

---

Response Biomedical Receives European Patent Notice of Allowance for Key Component of Immunoassay Intellectual Property
Wed, 6 Jan 2010 13:00:00 UT
Response Biomedical Corporation announced today that the Company has received a Notice of Allowance from the European Patent Office for the patent entitled “Sensitive Immunochromatographic Assay”, referred to as the “Fong Patent”. This critical patent protects key aspects of Response Biomedical’s lateral flow immunoassays conducted with the proprietary RAMP® testing platform. “The ‘Fong PatentR ...
More...

---